PDS Biotechnology Increases Authorized Shares; Annual Meeting Results

What Happened

• PDS Biotechnology Corporation filed an 8-K on August 14, 2026 reporting results of its August 10, 2026 Annual Meeting. Stockholders approved an amendment to the company’s Certificate of Incorporation increasing authorized common stock from 150,000,000 to 300,000,000 shares (par value $0.00033).
• The meeting also included the election of two Class B directors (Kamil Ali-Jackson, J.D. and Ilian Iliev, Ph.D.), ratification of KPMG US LLP as auditor for fiscal 2026, and a non-binding advisory approval of executive compensation.

Key Details

• Authorized shares: increased from 150,000,000 to 300,000,000 common shares; other charter provisions unchanged (Amendment filed as Exhibit 3.1).
• Meeting quorum: 31,594,722 shares represented (≈56.60% of 55,815,653 shares entitled to vote).
• Amendment vote: 19,904,111 For, 11,545,436 Against, 145,175 Abstaining.
• Other votes: Director elections — Kamil Ali-Jackson (8,986,360 For; 3,280,808 Withheld); Ilian Iliev (9,409,728 For; 2,857,440 Withheld). Auditor ratification — 30,351,424 For, 520,018 Against, 723,280 Abstain. Say-on-pay (advisory) — 7,237,690 For, 3,960,228 Against, 1,069,250 Abstain.

Why It Matters

• Increasing authorized common shares to 300 million does not itself issue new shares but gives the company the legal capacity to issue more common stock in the future (for financing, equity awards, M&A or other corporate purposes), which can affect the company’s total share count and potential dilution.
• Re-election of directors and ratification of KPMG provide continuity in governance and financial oversight. The advisory vote on executive pay passed (non-binding), reflecting stockholder sentiment but not changing compensation rules by itself.